CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for BioRegenx Inc is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

BioRegenx Inc
5051 Peachtree Corners Circle
Number 200, Suite 400
Phone: (404) 443-3224p:404 443-3224 NORCROSS, GA  30092  United States Ticker: BRGXBRGX

On 5/3/2024, the Securities and Exchange Commission (SEC) charged BF Borgers CPA PC and its owner, Benjamin F. Borgers, with significant violations of Public Company Accounting Oversight Board (PCAOB) standards across more than 1,500 SEC filings from January 2021 to June 2023. The charges included falsely representing compliance with PCAOB standards to clients, fabricating audit documentation, and inaccurately stating compliance in audit reports. According to the SEC's order, of 369 BF Borgers' clients whose public filings from January 2021 through June 2023 incorporated the firm's audits and reviews, at least 75 percent of the filings incorporated audits and reviews that did not comply with PCAOB standards. The financials in this report may include past audits and reviews conducted by BF Borgers CPA PC that are deemed not compliant with PCAOB standards.

Business Summary
BioRegenx, Inc. operates as a holding company specializing in acquiring intellectual property (IP) and companies engaged in regenerative biotherapeutics and anti-aging research. The Company’s subsidiaries include DocSun BioMedical Holdings, Inc. (DocSun), Microvascular Health Solutions, LLC (MVHS), MyBodyRx, LLC (MyBodyRx), NuLife Sciences, Inc. (NuLife) and Findit Ai Connect, Inc. (Findit Ai). DocSun combines three technologies in the DocSun Artificial Intelligence (AI) Engine. The DocSun AI Engine integrates advanced ballistocardiography, which can detect an individual's heartbeat without touch, and photoplethysmography, a method that uses light to track the flow of blood. MVHS specializes in research, product development, sales, and education, notably producing the patented Endocalyx Pro dietary supplement. MVHS also manufactures and distributes the patented GlycoCheck software and Class 1 medical devices. DocSun is also developing an app for NuLife, TruScan.Ai mobile app/Website.

Scores and Ratings
FRISK®
Score
Z''
Score
PAYCE®
Score
DBT
Index
Moody's
Rating
Fitch
Rating
DBRS
Rating
YesYes-----

Financials, News and Filings
Latest
Statement
Last
Audit

News
SEC
Filings
Bankruptcy
Filings
Suit &
Judgment
Filings
Tax
Lien
Filings
3/31/202512/31/2024YesYes--Yes

Officers and Directors

Title

Name

Age
Title
Date
Start
Date
President, Director DarrellFigg 3/8/2024 7/8/2004
Chief Executive Officer, Interim Chief Financial Officer, Director WilliamResides 55 3/8/2024
Treasurer, Director JohnSpicer 3/8/2024 11/29/2005
4 additional Officers and Directors records available in full report.

Business Names
Business Name
Austin Chalk Oil and Gas Ltd.
Austin Chalk Oil and Gas, Ltd.
BRGX
8 additional Business Names available in full report.

General Information
Number of Employees: 5 (As of 12/31/2024)
Outstanding Shares: 960,292,958 (As of 5/13/2025)
Shareholders: 300
Stock Exchange: OTC
Federal Tax Id: 912014670
Fax Number: (702) 866-2689
Email Address: info@sharewellcapital.com


Copyright © 2025 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Monday, June 2, 2025